Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; ... (2021). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic advances in neurological disorders, 14, p. 17562864211039648. Sage 10.1177/17562864211039648

[img]
Preview
Text
Wiendl__2021__MS_Therapy_Consensus_Group.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (405kB) | Preview

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Chan, Andrew Hao-Kuang

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1756-2856

Publisher:

Sage

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

25 Jan 2022 13:45

Last Modified:

05 Dec 2022 16:00

Publisher DOI:

10.1177/17562864211039648

PubMed ID:

34422112

Uncontrolled Keywords:

disease-modifying therapy guideline multiple sclerosis treatment recommendation

BORIS DOI:

10.48350/163566

URI:

https://boris.unibe.ch/id/eprint/163566

Actions (login required)

Edit item Edit item
Provide Feedback